Lymphoma Clinical Trials

Showing 601-620 of 1,633 trials

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

NCT03151057

This is a study to evaluate the safety of idelalisib as post-transplantation maintenance in patients with B cell hematologic malignancies undergoing a allogeneic hematopoietic stem cell transplant (HSCT). Safety will be evaluated through the assessment of cytopenias, effect on donor chimerism, effect on the incidence and severity of acute graft versus host disease, and gastro-intestinal tolerance.

B Cells-TumorsB Cell Chronic Lymphocytic LeukemiaFollicular Lymphoma+2 more

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins16 participantsStarted Jul 2018

Baltimore, Maryland, United States

TERMINATEDPHASE1/PHASE2

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

NCT02282358

The purpose of this study is to learn if the study drug mocetinostat can slow the progression of cancer in people who have a mutation in CREBBP or EP300 in the genetic makeup of their cancer. The potential side effects of mocetinostat will also be studied.

LymphomaRelapsed and RefractoryDiffuse Large B-Cell Lymphoma and Follicular Lymphoma

Memorial Sloan Kettering Cancer Center7 participantsStarted Oct 2014

New York, New York, United States

TERMINATEDPHASE1/PHASE2

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

NCT04509466

This is a multicentre, open-label, single-arm, phase I/II clinical study to evaluate the safety, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with pegaspargase in patients with extranodal natural killer/T-cell lymphoma, nasal type (NKTCL).

Extranodal NK/T-cell Lymphoma, Nasal Type

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.41 participantsStarted Sep 2020

Guiyang, Guizhou, China

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL

Related Searches

Chidamide Bridging for CAR-T Therapy

Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology

The Potential of Patient-reported Outcome Measures in Detection of Relapse in Diffuse Large B-cell Lymphoma

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Occupational Status and Hematological Disease

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Vaccination With Flt3L, Radiation, and Poly-ICLC

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Ipilimumab and Local Radiation for Selected Solid Tumors

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma